c-Met inhibition impairs progenitor cell mobilization. (A) Mice were injected with anti–c-Met Abs, 5 consecutive injections of G-CSF or anti–c-Met on days 4 and 5 of G-CSF administration. The frequency of circulating progenitor cells was analyzed. (B) Numbers of circulating progenitors in mice injected with vehicle, PHA, 5 consecutive doses of G-CSF with vehicle, or c-Met inhibitor. (C) A representative FACS analysis showing, in the upper lane, the percentage of circulating SKL cells in control mice or mice receiving c-Met Abs, or G-CSF alone or together with c-Met Abs. The lower lane depicts the percentage of SKL in the blood of mice injected with vehicle or c-Met inhibitor or G-CSF with vehicle or c-Met inhibitor. (D-E) A summary of ≥ 3 independent experiments showing the percentage of circulating SKL cells (D) in mice that were given anti–c-Met Abs, or G-CSF alone or G-CSF in combination with anti c-met Abs or (E) in mice that were injected with vehicle or with c-Met inhibitor, or G-CSF together with vehicle or c-Met inhibitor. (F) Percentage of circulating SKL/CD34⁻ cells in mice that were injected with vehicle, HGF, G-CSF together with vehicle, or c-Met inhibitor. In all the experiments, mobilization was evaluated after 3-5 hours after the last injection. (G) Representative FACS plot showing the percentage of CD34⁻ cells within the SKL population in the circulation of mice treated with DMSO, G-CSF and vehicle, or G-CSF and c-Met inhibitor. (H) Representative FACS plot showing the percentage of CD34⁻ cells within the SKL population in the circulation of mice treated with PBS or HGF. In all the experiments, mobilization was evaluated after 3-5 hours from the last injection. Indicated values are presented as mean ± SE in ≥ 3 independent experiments, 6 mice in each group. *P < .05; **P < .001.